Abstract
Eighty-seven patients from 18 institutions with a confirmed diagnosis of chronic myelogenous leukemia were registered on a Southwest Oncology Group protocol for multiagent induction and single-agent maintenance chemotherapy, with randomization to an immunotherapy arm. Elective surgical splenectomy was performed for 42 patients at the completion of 3 months of induction therapy. Final analysis of the study revealed statistically significant survival advantages were correlated with age, splenectomy, the absence of hepatic leukemic infiltrate at the time of splenectomy, and race.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Age Factors
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
BCG Vaccine / therapeutic use
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Female
-
Humans
-
Hydroxyurea / therapeutic use
-
Immunotherapy
-
Leukemia, Myeloid / therapy*
-
Male
-
Middle Aged
-
Prednisone / administration & dosage
-
Sex Factors
-
Splenectomy*
-
Vincristine / administration & dosage
Substances
-
BCG Vaccine
-
Cytarabine
-
Vincristine
-
Cyclophosphamide
-
Prednisone
-
Hydroxyurea